Page 1

Quidel Contact : Quidel Corporation Randy Steward Chief Financial Officer 858.552.7931 QUIDEL Media and Investors Contact : Quidel Corporation Ruben Argueta 858.646.8023 rargueta@quidel.com QUIDEL REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS SAN DIEGO , CA - August 5 , 2021 — - Quidel Corporation ( NASDAQ : QDEL ) a provider of rapid diagnostic testing solutions , cellular - based virology assays and molecular diagnostic systems , announced today financial results for the second quarter ended June 30 , 2021 . Second Quarter 2021 Highlights • • • Total revenue decreased 12 % to $ 176.6 million , from $ 201.8 million in the second quarter of 2020 . Total sales of COVID - 19 products were $ 83.4 million , as compared to $ 109.0 million in the second quarter of 2020 . Total sales of Influenza products were $ 1.6 million , as compared to $ 18.7 million in the second quarter of 2020 . Reported GAAP EPS of $ 0.45 per diluted share in the second quarter of 2021 , as compared to $ 1.55 per diluted share in the second quarter of 2020 . Reported non - GAAP EPS of $ 0.75 per diluted share in the second quarter of 2021 , as compared to $ 1.86 per diluted share in the second quarter of 2020 . Sofia ® SARS Antigen test received Emergency Use Authorization ( EUA ) for screening use with serial testing . Received amended EUA for new Sofia ® Q Rapid Antigen test device . Second Quarter 2021 Results Total revenue for the second quarter of 2021 was $ 176.6 million , versus $ 201.8 million for the second quarter of 2020. The 12 % decrease in sales from the second quarter of 2020 was driven by decreased demand for Sofia and PCR COVID - 19 assays that was partially offset by increased demand for QuickVue COVID - 19 tests , as well as lower demand for influenza products . This decrease was partially offset by 32 % growth from our Cardiometabolic Immunoassay product . Currency exchange impact was favorable by $ 2.8 million dollars . Excluding COVID - 19 and influenza products , revenue for the core business grew 24 % to $ 91.5 million , as compared to $ 74.0 million in the second quarter of 2020 . Rapid Immunoassay product revenue decreased by $ 20.5 million in the second quarter of 2021 to $ 60.1 million , due to lower revenue for our Sofia ® SARS Antigen and influenza products that were partially offset by $ 28.6 million in incremental Quick Vue SARS Antigen product sales . Cardiometabolic Immunoassay revenue totaled $ 71.7 million in the second quarter of 2021 , an increase of 32 % from the second quarter of 2020. Molecular Diagnostic Solutions revenue decreased $ 20.7 million to $ 34.5 million , due to a $ 25.5 million decline in sales of Lyra ® PCR assays for COVID - 19 diagnosis that was partially offset by incremental revenue from our Solana ® SARS - CoV - 2 assay . Specialized Diagnostic Solutions revenue decreased 12 % from the second quarter of 2020 to $ 10.4 million , driven by lower demand for respiratory testing . " During the second quarter of 2021 , we made great progress advancing our product portfolio , while continuing to position Quidel for long - term growth . In the quarter , we delivered solid 24 % growth in our core business , further broadened our installed base of Sofia Ⓡ analyzers and established a strong beachhead for COVID testing in the retail segment , ” said Douglas Bryant , president and CEO of Quidel Corporation . " We also made great strides in our R & D and Clinical efforts during the quarter , which set us up to execute on our multi - faceted growth strategy . Although the landscape of COVID testing continues to evolve daily , the highly transmissible COVID - 19 Delta variant is starting to drive demand in both the professional and OTC segments , ” continued Mr. Bryant . “ Further , the recent EUA